Schizophrenia.com

Minerva Neurosciences Presents Pre-Clinical Data Suggesting a Mechanistic Role of Roluperidone in Addressing Negative Symptoms of Schizophrenia

#1

Findings show roluperidone increases release and gene expression of BDNF, as well as release of GDNF

Data presented at 2019 Congress of the Schizophrenia International Research Society

WALTHAM, Mass., April 11, 2019 (GLOBE NEWSWIRE) – Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the presentation of a poster at the 2019 Congress of the Schizophrenia International Research Society in Orlando, Florida entitled Roluperidone increases in-vitro Brain-Derived Neurotrophic Factor (BDNF) release: a possible mechanistic role in negative symptoms?

Findings to be presented in Poster #T145 during Poster Session 1 on April 11, 2019, 12:00 p.m. – 2:00 p.m., demonstrate that administration of roluperidone significantly increased BDNF release by astrocytes and hippocampal neurons obtained from the cerebral cortex of newborn rats, as well as the release of GDNF (Glial cell derived neurotrophic factor) in cultured astrocytes. Furthermore, data showed that roluperidone enhanced BDNF gene expression at drug concentrations similar to those observed in humans at tested doses.

Based on these results, researchers suggested that the effect of roluperidone on BDNF and GDNF may indicate the potential of this investigational compound for disease modification and improved neuroplasticity, in addition to its observed effects on the sigma2 and serotoninergic 5-HT2A neurotransmitter pathways.

BDNF is a member of a family of proteins called neurotrophins that plays an important role in the formation and function of neural connections. BDNF is the most widely distributed neurotrophin in the brain and has been associated with neurogenesis, neuroplasticity, neuroprotection, synapse regulation, learning, and memory.1 Its involvement in schizophrenia has also been described.2 GDNF is another neurotrophin that is known to promote the survival of different types of brain cells and has been shown to be essential for the maintenance and survival of dopamine neurons.3

4 Likes
#2

Sounds good, I hope that means that we’ll see people on it longer term getting even more benefits.

3 Likes